In this letter, written after her first congressional testimony on the issue of recombinant DNA research, Singer insisted that NIH guidelines "afford confidence that potentially dangerous recombinants will not escape from laboratory situations," and that regulation through federal legislation was not required to ensure public and laboratory safety.
Copyright:
This item may be under copyright protection; contact the copyright owner for permission before re-use.